Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Author:
United States | Publication | January 2021
On December 23, 2020, Governor Tim Walz signed three emergency executive orders regarding the state’s COVID-19 response.
Emergency Executive Order 20-107 authorizes out-of-state pharmacists—who hold an active, relevant license, certificate or other permit in good standing issued by a state of the United States or the District of Columbia—to administer COVID-19 vaccines in Minnesota during the COVID-19 Peacetime Emergency.
Additionally, Emergency Executive Order 20-106 rescinds Executive Order 20-34, which directed the Minnesota Commissioner of Health to share limited health information—the addresses where a positive COVID-19 test result has been obtained and whether the individual tested is still contagious to others—with the Department of Public Safety. Executive Order 20-106 also rescinds Executive Order 15-15, which established the Governor’s Committee to advise the Minnesota Pollution Control Agency (MPCA). The Committee was tasked with providing input and recommendations prior to certain regulatory decisions made by the MPCA.
Finally, Emergency Executive Order 20-105 extends a 10 percent salary reduction for the Governor and his Chief of Staff through July 1, 2021.Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Africa faces a stark reality: contributing less than 4% of global greenhouse gas emissions, the continent is disproportionately impacted by climate change, threatening its development and stability.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023